GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Newron Pharmaceuticals SpA (XTER:NP5) » Definitions » Cash And Cash Equivalents

Newron Pharmaceuticals SpA (XTER:NP5) Cash And Cash Equivalents : €7.90 Mil (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Newron Pharmaceuticals SpA Cash And Cash Equivalents?

Newron Pharmaceuticals SpA's quarterly cash and cash equivalents declined from Jun. 2023 (€7.71 Mil) to Dec. 2023 (€6.34 Mil) but then increased from Dec. 2023 (€6.34 Mil) to Jun. 2024 (€7.90 Mil).

Newron Pharmaceuticals SpA's annual cash and cash equivalents declined from Dec. 2021 (€25.02 Mil) to Dec. 2022 (€13.42 Mil) and declined from Dec. 2022 (€13.42 Mil) to Dec. 2023 (€6.34 Mil).


Newron Pharmaceuticals SpA Cash And Cash Equivalents Historical Data

The historical data trend for Newron Pharmaceuticals SpA's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newron Pharmaceuticals SpA Cash And Cash Equivalents Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.05 13.21 25.02 13.42 6.34

Newron Pharmaceuticals SpA Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.88 13.42 7.71 6.34 7.90

Newron Pharmaceuticals SpA Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Newron Pharmaceuticals SpA  (XTER:NP5) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Newron Pharmaceuticals SpA Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Newron Pharmaceuticals SpA's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Newron Pharmaceuticals SpA Business Description

Traded in Other Exchanges
Address
Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.
Executives
Stefan Weber Board of Directors
Dr. Ulrich Köstlin Supervisory Board

Newron Pharmaceuticals SpA Headlines

No Headlines